ImmunityBio, Inc. (IBRX)
8.625
-0.56
(-6.05%)
USD |
NASDAQ |
Oct 19, 14:45
ImmunityBio Cash from Operations (Annual) : -304.94M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -304.94M |
| December 31, 2024 | -391.24M |
| December 31, 2023 | -366.76M |
| December 31, 2022 | -337.51M |
| December 31, 2021 | -274.42M |
| December 31, 2020 | -70.45M |
| December 31, 2019 | -61.36M |
| Date | Value |
|---|---|
| December 31, 2018 | -63.38M |
| December 31, 2017 | -48.78M |
| December 31, 2016 | -38.59M |
| December 31, 2015 | -25.30M |
| December 31, 2014 | -5.418M |
| December 31, 2013 | -0.668M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Moderna, Inc. | -1.873B |
| Sarepta Therapeutics, Inc. | -222.54M |
| Arrowhead Pharmaceuticals, Inc. | 179.55M |
| Oncolytics Biotech, Inc. | -20.11M |
| Sangamo Therapeutics, Inc. | -97.21M |